<DOC>
	<DOCNO>NCT01394640</DOCNO>
	<brief_summary>Primary objective 1 ) To assess whether oncologic hematologic patient develop protective immunological response pandemic Influenza A ( H1N1 ) vaccine Secondary objectives 1 . To compare level antibody response A ( H1N1 ) influenza virus oncologic hematologic patient relative cohort healthy volunteer 2 . To assess incidence A ( H1N1 ) infection vaccinate oncologic hematologic patient comparison cohort vaccinate healthy volunteer . To assess clinical symptom attributable influenza infection vaccinate oncologic hematological patient healthy volunteer . 3 . To compare level antibody response A ( H1N1 ) influenza virus follow subgroup : patient ongoing chemotherapy ; patient complete chemotherapy treatment ; patient treat autologous allogeneic peripheral blood hematopoietic stem cell transplant ( PBSCT ) Study procedure : Onco-hematological patient perform blood sample collection vaccination , day +21 vaccination , day +50 day +90 . At end collection , investigator perform immunological test evaluate antibody titer cellular response . The titer antibody vaccine strain measure sample hemagglutination-inhibition ( HI ) assay use turkey erythrocyte accord EMEA guideline . Response criteria achievement protective title HI test &gt; 1:40 . In addition , investigator evaluate : geometric mean titer fourfold titer increase compare prevaccination titer . Cellular-mediated response analyse flow-cytometry . A control cohort healthy volunteer receive A ( H1N1 ) vaccine perform blood sample collection . Evaluation clinical response : Oncologic hematologic patient follow outpatient inpatient accord routine control disease . In case symptom upper airways influenza-like symptom develop , symptom record clinical database , nasal pharyngeal swap perform accord doctor take care patient . In order evaluate clinical efficacy vaccination , swap test A ( H1N1 ) influenza virus infection . No study perform 3 month vaccination .</brief_summary>
	<brief_title>Immunologic Response After Pandemic Influenza A ( H1N1 ) Vaccine Onco- Hematologic Patients</brief_title>
	<detailed_description>Primary objective 1 ) To assess whether oncologic hematologic patient develop protective immunological response pandemic Influenza A ( H1N1 ) vaccine Secondary objectives 1 . To compare level antibody response A ( H1N1 ) influenza virus oncologic hematologic patient relative cohort healthy volunteer 2 . To assess incidence A ( H1N1 ) infection vaccinate oncologic hematologic patient comparison cohort vaccinate healthy volunteer . To assess clinical symptom attributable influenza infection vaccinate oncologic hematological patient healthy volunteer . 3 . To compare level antibody response A ( H1N1 ) influenza virus follow subgroup : patient ongoing chemotherapy ; patient complete chemotherapy treatment ; patient treat autologous allogeneic peripheral blood hematopoietic stem cell transplant ( PBSCT ) Study population design The study population consist consecutive patient oncologic hematologic disease plan receive A ( H1N1 ) influenza vaccine Study procedures The patient perform blood sample collection ( serum vial ) day 0 ( range : 0- 2 day vaccination ) vaccination , blood sample collection ( serum vial ) day +21 ( range : +/- 5 day ) vaccination , blood sample collection ( serum vial ) day +50 ( range : +/- 5 day ) day +90 range : +/- 5 day ) vaccination . The sample freeze 500 mcl aliquot -20°C . At end collection perform immunological test evaluate antibody titer cellular response . The serum sample store laboratory Virology University Milan . The titer antibody vaccine strain measure sample mean hemagglutination-inhibition ( HI ) assay use turkey erythrocyte accord EMEA guideline . Response criteria achievement protective title HI test &gt; 1:40 . In addition evaluate : geometric mean titer fourfold titer increase compare prevaccination titer . Cellular-mediated response analyse incubate CD3+ patient ' cell influenza A Antigens evaluation : 1 ) cellular expansion flow-cytometry analysis dilution carboxyfluorescein succinimidyl ester ( CFSE ) ; 2 ) IFN-gamma production ELISPOT . A control cohort healthy volunteer receive A ( H1N1 ) vaccine perform blood sample collection order compare immunological response oncologic hematologic patient relative healthy cohort . Evaluation clinical response : Oncologic hematologic patient follow outpatient inpatient accord routine control disease . In case symptom upper airways influenza-like symptom develop , symptom record clinical database , nasal pharyngeal swap perform accord doctor take care patient . In order evaluate clinical efficacy vaccination , swap test A ( H1N1 ) influenza virus infection . No study perform 3 month vaccination . Sample size The trial accrue 25 patient subpopulation analyze . This sample size 90 % power evaluate increase probability biological response theoretical value 20 % ( low efficacy vaccine ) value 50 % ( target effectiveness ) 5 % significance ( student test , one tail ) . The subpopulation follow : patient ongoing chemotherapy ; patient complete chemotherapy treatment ; patient treat autologous allogeneic transplant hematopoietic stem cell . We accrue `` calibration '' group comprise least 100 healthy volunteer . This group comprise people work National Cancer Institute Milan sign inform consent participate study . This size sample allow precision evaluation probability obtain biological response ( half confidence interval ) low 10 % Study duration The estimate duration enrolment 6 month . The enrolment hematologic oncologic patient cohort healthy volunteer perform 3 month study close day +90 blood sample collection . Selection criterion Inclusion criterion - Age ≥18 year - Oncologic hematologic patient plan receive A ( H1N1 ) vaccine - Control Group : silent history oncologic hematologic disease ; plan receive A ( H1N1 ) vaccine - Written inform consent Exclusion criterion - Infusion human Immunoglobulin ongoing within prior 30 day - Therapy monoclonal polyclonal antibody ongoing within prior 30 day - Therapy IL-1 IL-2 IFN-gamma ongoing within prior 30 day - Autologous PBSCT le 1 month Allogeneic PBSCT le 6 month - Pregnancy lactation - Type I hypersensitivity - Ongoing Anticoagulant therapy platelet &lt; 50000/ul Study Procedures baseline : Medical history oncologic hematologic disease ; gynecologic history woman 50 year age • Serum sample day vaccination 2 day advance</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age ≥18 year Oncologic hematologic patient plan receive A ( H1N1 ) vaccine Control Group : silent history oncologic hematologic disease ; plan receive A ( H1N1 ) vaccine Written inform consent Infusion human Immunoglobulin ongoing within prior 30 day Therapy monoclonal polyclonal antibody ongoing within prior 30 day Therapy IL1 IL2 IFNgamma ongoing within prior 30 day Autologous PBSCT le 1 month Allogeneic PBSCT le 6 month Pregnancy lactation Type I hypersensitivity Ongoing Anticoagulant therapy platelet &lt; 50000/ul</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>